GliosarcomaSymptoms, Doctors, Treatments, Advances & More
Learn About Gliosarcoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Johns Hopkins Outpatient Center
Henry Brem is a Neurosurgery provider practicing medicine in Baltimore, Maryland. Dr. Brem is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Gliosarcoma, Glioma, Gliomatosis Cerebri, Osteotomy, and Posterior Fossa Decompression. Dr. Brem is board certified in American Board Of Neurological Surgery.
Dana-Farber Cancer Institute, Center For Neuro-Oncology
Patrick Wen is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Wen is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Wen is board certified in Neurology and Neuro-Oncology.
Egil And Pauline Braathen Center/Maroone Cancer Center
Surabhi Ranjan is a Neurologist practicing medicine in Weston, Florida. Dr. Ranjan is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. She is also highly rated in 24 other conditions, according to our data. Her clinical expertise encompasses Gliosarcoma, Metastatic Brain Tumor, Brain Tumor, and Glioma. Dr. Ranjan is board certified in American Board Of Psychiatry And Neurology, 2015.
Summary: This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
Summary: WinGlio is a phase I study investigating neoadjuvant (before surgery) ipilimumab ( a type of immunotherapy drug) in patients with newly diagnosed glioblastoma (a form of brain cancer). Participants will receive up to 2 cycles of ipilimumab prior to the standard of care treatments for this patient group which can include debulking surgery and chemoradiation. The aim of giving the ipilimumab to the ...